

REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. §121 and 372:

Group I - Claims 1, 5, 13-15, 17 and 20, drawn to methods of diagnosis comprising detecting/quantifying SC6 *polypeptide* in a biological sample.

Group II - Claims 2, 16, and 19, drawn to methods of diagnosis comprising detecting/quantifying SC6 *nucleic acid* in a biological sample.

Group III - Claims 3-4, drawn to antibodies that bind an SC6 polypeptide.

Group IV - Claims 6-8 (in part) in so far as they are drawn to a method for screening agents that modulate the activity of an SC6 polypeptide.

Group V - Claims 6 and 8 (in part) in so far as they are drawn to a method for screening agents that modulate the expression of an SC6 polynucleotide or polypeptide.

Group VI - Claim 8 (in part), in so far as it is drawn to an agent of undisclosed constitution that inhibits or down-regulates the activity of an SC6 polypeptide.

Group VII - Claim 8 (in part), in so far as it is drawn to an agent of undisclosed constitution that inhibits or down-regulates the expression of an SC6 polynucleotide or polypeptide.

Group VIII - Claims 10, 18 and 21 (in part), in so far as they are drawn to methods of treatment comprising administering an SC6 polypeptide.

Group IX - Claims 10, 18, and 21 (in part), in so far as they are drawn to methods of treatment comprising administering an SC6 polynucleotide.

Group X - Claims 10, 18 and 21 (in part), in so far as they are drawn to methods of treatment comprising administering an agent which inhibits or down-regulates the expression of an SC6 polypeptide.

Group XI – Claims 10, 13, 18 and 21 (in part), in so far as they are drawn to methods of treatment comprising administering an agent which inhibits or down-regulates the activity of an SC6 polypeptide.

Responsive to the Requirement for restriction, Applicants elect to prosecute the invention of **Group I**, namely Claims 1, 5, 13-15, 17 and 20, directed to methods of diagnosis comprising detecting/quantifying SC6 *polypeptide* in a biological sample without traverse.

The Examiner has further required the election of a distinct species of the claimed Groups I, II, III, IV, V, VI, VII, VII, IX, X, XI, wherein the species are:


- Species 1: Cervical Cancer
- Species 2: Colon Cancer
- Species 3: Renal Cancer
- Species 4: Lung Cancer
- Species 5: Uterine Cancer
- Species 6: Breast Cancer
- Species 7: Pancreatic Cell Carcinoma
- Species 8: Lymphoma
- Species 9: Leukaemia

Applicant elects Species 1 directed to Cervical Cancer without traverse. Claims 14, 15, 17 and 20 are all readable on this elected species.

No fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

In view of the above, withdrawal of the Requirement for the Restriction is requested, and an early action on the merits of the Claims is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON LLC
411 Hackensack Avenue, 4TH Floor
Hackensack, New Jersey 07601
(201) 487-5800

Date: December 7, 2006